Yüklüyor......
Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma
In the absence of a driver mutation, chemotherapy is the standard treatment option as first- and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large number of patients are suitable for post second-line therapies, the quality and quantity of the available drugs in this...
Kaydedildi:
| Yayımlandı: | Onco Targets Ther |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5261838/ https://ncbi.nlm.nih.gov/pubmed/28176910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S126613 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|